Selection, design, and engineering of therapeutic antibodies.
mAbs account for an increasing portion of marketed human biological therapeutics. As a consequence, the importance of optimal selection, design, and engineering of these not only has expanded in the past 2 decades but also is now coming into play as a competitive factor. This review delineates the 4 basic areas for optimal therapeutic antibody selection and provides examples of the increasing number of considerations necessary for, and options available for, antibody design. Though some of the advances in antibody technology (eg, antibodies derived from phage-display libraries) have already made it to market, other more recent advances, such as engineering antibodies for enhanced effector functions, may not be far behind, especially given the increasing competition for therapeutic antibodies to the same target (eg, anti-CD20 and anti-TNF-alpha).
Presta
Leonard G
LG
Schering-Plough Biopharma, Pali Alto, CA 94304, USA. leonard.presta@spcorp.com
D000595:Amino Acid Sequence; D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000235:genetics / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity; D022801:Complementarity Determining Regions; D015195:Drug Design; D000939:Epitopes; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000737:chemistry / Q000235:genetics / Q000627:therapeutic use; D051379:Mice; D015202:Protein Engineering
D000911:Antibodies, Monoclonal; D022801:Complementarity Determining Regions; D000939:Epitopes; D007141:Immunoglobulin Fc Fragments